# Neuroscience Based Nomenclature: redefining psychiatric drug nomenclature for reducing stigma and improving treatment selection

Rafael Nogueira-Marques[1,2], Camila F. Secco Bastos[1], Joseph Zohar[3], Marlene. Santos[1]*
[1] *REQUIMTE|LAQV, Escola Superior de Saúde, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida 431, 4200-072 Porto, Portugal.*
[2] *Universidade de Vigo, Nutrition and Food Group (NuFoG), Department of Analytical Chemistry and Food Science, Instituto de Agroecoloxía e Alimentación (IAA) – CITEXVI, 36310 Vigo, Spain.*
[3] *Post-Trauma Center, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel*
* *Autor correspondente*

**Framework:** With advances in pharmacology, the traditional nomenclature of psychiatric medications has failed to keep pace with current knowledge and does not accurately inform stakeholders. For instance, if a patient takes quetiapine, classified as an antipsychotic, does that imply they have schizophrenia or a depressive disorder? [1] This ambiguity highlights the need for a revised classification system that reflects modern neuroscience. The Neuroscience Based Nomenclature (NbN addresses this issue by categorizing psychiatric medications based on their pharmacological properties rather than outdated diagnostic labels. [2,3] **Objectives:** Therefore, this project aims to promote the adoption of NbN by developing and implementing a **Massive Open Online Course (MOOC)** for healthcare professionals (HPs). The MOOC will assess the practical application of NbN, identify challenges in its use, and explore opportunities for improvement. **Methodology:** The NbN software application will be disseminated among students and healthcare professionals to encourage engagement. A questionnaire will be used to assess learning challenges, which will inform the structure of the MOOC. Following its implementation, the course's impact will be monitored, and recommendations for further improvements will be made to support broader societal adoption [4]. **Expected outcomes:** This project is expected to enhance HP understanding of NbN and its clinical applicability, facilitate the adoption of this neuroscience-based classification, and improve communication between professionals and patients. By reducing stigma and ensuring more precise prescriptions, this initiative aims to contribute to better mental health care.

**Keywords:** Neuroscience Based Nomenclature; Psychiatry; Pharmacology; Healthcare professionals

**Reconhecimentos**
Rafael Nogueira-Marques e Camila F. Secco Bastos receberam financiamento pela Bolsa INNOVHEATH no âmbito do programa Impulso Jovens STEAM do Programa Resilient P.PORTO, cofinanciado pelos fundos do programa «Next Generation EU» do Plano de Recuperação e Resiliência (PRR).

**Referências**

1. Infarmed. Consulta de princípios ativos - Quetiapina. Disponível em: https://app10.infarmed.pt/prontuario/framepesactivos.php?palavra=quetiapina&x=0&y=0&rb1=0. Acesso em: 5 mar. 2025.
2. Galduroz JCF, Zampronio AR, Vital MABF, Sallet PC, Zohar J, Andreatini R. Neuroscience-Based Nomenclature (NbN): the Portuguese version of the new classification for psychopharmacological drugs. Trends Psychiatry Psychother. 2024; Ahead of Print. doi:10.47626/2237-6089-2023-0771.
3. Zohar J, Stahl S, Möller HJ, Blier P, Kupfer D, Yamawaki S, et al. Neuroscience-based Nomenclature (NbN). Cambridge University Press; 2014.
4. Neuroscience-based Nomenclature (NbN). Disponível em: https://www.nbn.science. Acesso em: 5 mar. 2025.